Kashmira Mayank*, Kumar Kapil, Kapoor Rajesh and Singh Vaibhav

Department of GI and Hepato-Pancreatico- Biliary Surgery, Jaypee Hospital, Noida (U.P), India

*Corresponding Author: Kashmira Mayank, Department of GI and Hepato Pancreatico- Biliary Surgery, Jaypee Hospital, Noida (U.P), India.

Received: December 12, 2024; Published: December 16, 2024

Abstract

Background: Dabigatran is a direct oral anticoagulant (DOAC) that acts by blocking thrombogenic activity and preventing thrombus formation. However, dabigatran induced oesophageal mucosal injury is often neglected as one potential complication of dabigatran. Here we present a rare case report of an elderly Asian male presenting with dysphagia, diagnosed as dabigatran induced keratosis with oesophageal mass extending into stomach revealing carcinoma cuniculatum on histopathology.

Case Presentation: A 62-year-old Asian male came to hospital with history of dysphagia and sticking sensation in the throat for 2 years and recent onset recurrent fall in haemoglobin with black coloured stools. The patient was a known case of type II diabetes for 25 years (on regular medication) and peripheral vascular disease, had stent placement in the left superficial femoral artery 10 years back and was on dabigatran since then. Endoscopy showed significant ulcerations with whitish flakes starting from the 29 cm and extends till the GE junction. At 32 cm, there was a large fungating lesion causing luminal compromise. Fungating lesion was extend ing up to the fundus with an area with adherent clot over it. As the clot was removed, a spurter was noted which was coagulated with APC probe. Patient was planned for resection of the mass. Intraoperatively a 3cm x 3cm ?? oval shaped mass lesion of oesophageal origin extending into lesser curvature of the stomach was found. Partial gastrectomy with resection of the mass lesion was done. Post operatively patient developed pulmonary complications which were managed conservatively with supportive care.

Conclusion: Our case highlights the importance of awareness on the part of the physician about the esophagitis as a possible com plication of dabigatran and reporting Carcinoma cuniculatum of oesophagus extending into stomach which is an extremely rare and often indolent cancer.

Keywords: Case Report; Dabigatran; Esophagitis; DIE (Dabigatran Induced Esophagitis)

References

1. Lip GYH., et al. “Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report”. Chest154 (2018): 1121-1201.
2. Okada M and Okada K. “Exfoliative esophagitis and esophageal ulcer induced by dabigatran”. Endoscopy44 (2012):  E23-24. 
3. Singh S., et al. “Severe necrotic oesophageal and gastric ulceration associated with dabigatran”. BMJ Case Report(2013): 1-3.
4. Ootani A., et al. “Dabigatran-induced esophagitis”. Clinical Gastroenterology and Hepatology 12 (2014): e55-56.
5. Zimmer V., et al. “Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma”. Endoscopy46 (2014): E273-E274.
6. Scheppach W and Meesmann M. “Exfoliative esophagitis while taking dabigatran”. 
   Deutsche Medizinische Wochenschrift 140 (2015): 515-518.
7. Shibagaki K., et al. “Dabigatran-induced asymptomatic esophageal mucosal injury”. Gastrointestinal Endoscopy 83 (2016): 472-474.
8. Yoshimitsu M., et al. “Dabigatran-induced exfoliative esophagitis”. Internal Medicine 55 (2016):
9. Cuadros Martínez M., et al. “Symptomatic exfoliative esophagitis induced by dabigatran”. Revista Española de Enfermedades Digestivas 110 (2018): 743-744.
10. Matsumoto Y., et al. “Dabigatran-induced esophagitis associated with vomiting”. American Journal of Gastroenterology 114 (2019):
11. January CT., et al. “2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society”. Journal of the American College of Cardiology 74 (2019): 104-132.
12. Zhang N., et al. “Dabigatran-induced esophagitis: A frequently overlooked adverse effect”. International Journal of Cardiology 212 (2016): 358-359. 
13. Toya Y., et al. “Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics”. Journal of Gastroenterology and Hepatology 31 (2016): 610-614.
14. Zhou Y., et al. “Dabigatran-induced esophagitis: A case report”. Medicine (Baltimore) 99 (2020): e19890.

Citation

Citation: Kashmira Mayank., et al. “Dabigatran Induced Oesophageal Keratosis Presenting as Bleeding Carcinoma Cuniculatum: A Case Report". A Acta Scientific Gastrointestinal Disorders 8.1 (2025): 08-14.

Copyright

Copyright: © 2025 Kashmira Mayank., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.